Omnicef O CV 200mg/125mg Tablet is a combination antibiotic formulation containing Cefixime 200mg and Clavulanic Acid 125mg. Cefixime, a third-generation cephalosporin, exhibits broad-spectrum bactericidal activity by inhibiting bacterial cell wall synthesis, effective against a wide range of gram-positive and gram-negative pathogens. Clavulanic Acid acts as a beta-lactamase inhibitor, preventing enzymatic degradation of Cefixime by beta-lactamase-producing bacteria, thereby enhancing its efficacy against resistant strains. This synergistic combination is indicated for the treatment of various bacterial infections including respiratory tract infections, urinary tract infections, otitis media, and skin and soft tissue infections caused by susceptible organisms. Omnicef O CV is particularly useful in cases where resistance to beta-lactam antibiotics is suspected or confirmed. The tablet is administered orally, with dosage and duration tailored according to the severity and type of infection, as well as patient-specific factors such as age and renal function. Common adverse effects may include gastrointestinal disturbances such as diarrhea, nausea, and abdominal discomfort. Caution is advised in patients with a history of hypersensitivity to cephalosporins or penicillins. Use during pregnancy and lactation should be under medical supervision. Proper adherence to prescribed therapy is essential to prevent resistance development and ensure clinical efficacy.